Crown Bioscience Enters Global Agreement with Shanghai Model Organism Center

On June 4, 2024 Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, reported the completion of a global collaboration agreement with the Shanghai Model Organisms Center (SMOC) (Press release, Crown Bioscience, JUN 5, 2024, View Source [SID1234644095]). This five-year agreement extends the existing partnership and will provide unique immuno-oncology platforms and services from all Crown Bioscience facilities worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This strategic alliance includes:

The purchase and supply of a broad range of genetically engineered mouse models, including thousands of knock-in and knock-out humanized models,

Genetically engineered cell line development services,

Custom development of GEMM models and MuPrimeTM (Crown Bioscience’s tumor homograft models) leveraging SMOC-engineered mice.
Globally, Crown Bioscience research affiliates will benefit from uniform pricing, comprehensive IP protection, and licensing rights. This uniformity is accompanied by a shared commitment to research excellence, unrivaled quality standards, and scientific innovation.

Key advantages for Crown Bioscience customers include:

Unprecedented Access: Immediate access to SMOC’s extensive library, featuring over 6,000 off-the-shelf mouse models and more than 11,000 established genetically engineered mouse prototypes.

Consistent Supply Chain: A reliable source of genetically engineered cell lines and murine models, alongside highly translational humanized models.

Global Strategic Synergy: Fostering a global strategic partnership, extending beyond procurement, that enhances both entities’ capabilities and offerings.
Through this collaboration, Crown Bioscience and SMOC will help bridge the gap between scientific discovery and clinical application and foster the continuous growth and evolution of global research initiatives.

Click here for more information on our innovative immuno-oncology platforms and services.